Elena Heras-Recuero

Elena Heras-Recuero

Auto-generated profile, based on publicly available information

Elena Heras-Recuero

Division of Rheumatology, Instituto de Investigación Sanitaria Fundación Jiménez Díaz , Madrid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2024 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
MHMarta Hernández-Díaz
Marta Hernández-Díaz
DGDara Rodríguez González
Dara Rodríguez González
EHElena Heras-Recuero
Elena Heras-Recuero
FGFuensanta Gómez
Fuensanta Gómez
JQJuan Carlos Quevedo-Abeledo
Juan Carlos Quevedo-Abeledo
IFIván Ferraz-Amaro
Iván Ferraz-Amaro
Background: Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular (CV) events and CV mortality. Subclinical carotid atherosclerosis is independently associated with rates of incident CV events among patients with RA. The complement system has been related to both the etiopathogenesis of RA and CV disease. In this study, we aimed to evaluate the association between a comprehensive assessment of the complement system and carotid intima media thickness and carotid plaque in patients with RA. Methods: 430 patients with RA were recruited. Functional assays of the three pathways of the complement system, utilizing new-generation techniques, were assessed. Additionally, serum levels of individual components of the complement system belonging to the three pathways were measured: C1q (classical), lectin (lectin), C2, C4, and C4b (classical and lectin), factor D and properdin (alternative), C3 and C3a (common), C5, C5a, and C9 (terminal), as well as regulators factor I and C1-inhibitor. Subclinical carotid atherosclerosis was evaluated by ultrasonography. Multivariable linear regression analysis was conducted to investigate the association between the complement system and carotid intima media thickness and carotid plaque. Results: After multivariable adjustment, which included traditional CV risk factors and disease-related data, C3a and C5a exhibited significant positive correlations with carotid intima media thickness. Additionally, higher values of C1-inhibitor, properdin, C3, C5, and C5a were independently associated with the presence of carotid plaque. Conclusion: The complement system and subclinical carotid atherosclerosis are linked in patients with RA.

21 May 2025 in Rheumatology
Verified
Journal Article
Closed access
IFIván Ferraz-Amaro
Iván Ferraz-Amaro
EHElena Heras-Recuero
Elena Heras-Recuero
AVAntonia de Vera-González
Antonia de Vera-González
ADAlejandra González Delgado
Alejandra González Delgado
ARAlejandro Romo-Cordero
Alejandro Romo-Cordero
Miguel Angel Gonzalez-GayMiguel Angel Gonzalez-Gay
Miguel Angel Gonzalez-Gay
Objectives: The Fibrosis-4 index (FIB-4), a non-invasive tool for assessing liver fibrosis, has also been linked to cardiovascular (CV) risk in the general population. This connection is due to the association of chronic liver diseases, particularly fibrosis or non-alcoholic fatty liver disease, with systemic inflammation, metabolic syndrome and atherosclerosis. In this study, we aimed to calculate the FIB-4 index in patients with rheumatoid arthritis (RA), a condition associated with increased CV disease risk. We then examined its association with disease characteristics and CV comorbidities, including lipid profile, subclinical carotid atherosclerosis and insulin resistance indices. Methods: A total of 465 RA patients were recruited in this cross-sectional study. They underwent comprehensive evaluations, including disease-related features, complete lipid profile, anthropometric measurements, insulin resistance indices (using HOMA), metabolic syndrome criteria, and carotid ultrasound for intima-media thickness and carotid plaque detection. FIB-4 was calculated and categorized into low (3.25) risk for fibrosis. A multivariable linear regression analysis was performed to examine the associations between the disease characteristics and FIB-4. Results: Twenty percent of RA patients had a FIB-4 score indicating indeterminate or high risk for hepatic fibrosis. FIB-4 was significantly associated with higher values of the cardiovascular risk calculator SCORE2 but not with carotid atherosclerosis. It was also significantly related to insulin resistance and metabolic syndrome. However, after multivariable analysis, FIB-4 did not correlate with RA disease characteristics, including disease activity. Conclusion: Up to 20% of RA patients show an abnormal FIB-4 index, which correlates with cardiovascular risk and insulin resistance.

26 April 2026 in Rheumatology
Verified
Journal Article
Closed access
Miguel Angel Gonzalez-GayMiguel Angel Gonzalez-Gay
Miguel Angel Gonzalez-Gay
FGFuensanta Gómez
Fuensanta Gómez
EHElena Heras-Recuero
Elena Heras-Recuero
JQJuan Carlos Quevedo-Abeledo
Juan Carlos Quevedo-Abeledo
ATArantxa Torres-Roselló
Arantxa Torres-Roselló
IFIván Ferraz-Amaro
Iván Ferraz-Amaro
Objectives: SLE is associated with a higher risk of metabolic syndrome compared with the general population. IFN-α and IFN-γ have been implicated in the pathogenesis of SLE. However, their serum quantification has been challenging until the development of ultrasensitive detection techniques. In this study, we aimed to examine the relationship between IFN-α and IFN-γ values and lipid profile abnormalities as well as pancreatic β-cell dysfunction, both of which are linked to the metabolic syndrome observed in patients with SLE. Methods: : A total of 313 patients with SLE were recruited. A panel of cardiovascular characteristics was collected, including lipid profiles and indices of insulin resistance. Serum IFN-α and IFN-γ levels were measured using an innovative ultrasensitive technique (single molecule array). Multivariable linear regression analysis was performed to examine the relationships between serum IFN-α and IFN-γ concentrations and both the lipid profile and insulin resistance indices Results: After multivariable adjustment for classical cardiovascular risk factors and SLE disease activity, IFN‑α and IFN‑γ levels were found to be associated with an adverse lipid profile and insulin resistance indices. Specifically, IFN‑α showed significant positive associations with triglycerides, low-density-lipoprotein cholesterol, lipoprotein(a), and the atherogenic index, and a negative association with high-density-lipoprotein cholesterol. Remarkably, these associations remained significant after adjustment for IFN‑γ. Conversely, IFN‑γ was significantly and positively associated with triglycerides and pancreatic β‑cell dysfunction, after adjustment for covariates, including serum IFN‑α levels. Conclusion: Serum IFN‑α and IFN‑γ are independently associated with key components of metabolic syndrome in SLE, including dyslipidaemia and pancreatic β‑cell dysfunction.

4 November 2024 in Rheumatology
Verified
Journal Article
Closed access
PDF file
IFIván Ferraz-Amaro
Iván Ferraz-Amaro
EHElena Heras-Recuero
Elena Heras-Recuero
JQJuan Carlos Quevedo-Abeledo
Juan Carlos Quevedo-Abeledo
JLJavier Llorca
Javier Llorca
Miguel Angel Gonzalez-GayMiguel Angel Gonzalez-Gay
Miguel Angel Gonzalez-Gay
Cardiovascular (CV) disease is the leading cause of death among patients with systemic lupus erythematosus (SLE). This study aimed to compare the performance of QRESEARCH-risk estimator version 3 (QRISK3) and the Systematic Coronary Risk Evaluation-2 (SCORE2) scores to identify SLE patients at high risk of CV events, as indicated by the presence of carotid plaques. Subclinical atherosclerosis was evaluated using carotid ultrasound in 365 SLE patients. QRISK3 and SCORE2 were calculated. The relationship between these scores and the presence of carotid plaques was analyzed by treating the scores as continuous and categorical variables, and separately and in combination. Logistic regression and area under the receiver operating characteristic curve (AUC) analyses were used to assess their predictive accuracy. The discriminatory capacity of QRISK3, with an AUC of 0.770 (95%CI : 0.720, 0.821), and SCORE2, with an AUC of 0.800 (95%CI : 0.753, 0.843), for carotid plaque was similar, with no statistically significant difference (p= 0.070). However, when examining the association of both calculators considered continuously and together with their interaction, the discriminatory capacity of this combination was significantly greater than that of QRISK3 alone (p= 0.034) but did not differ from SCORE2 (p= 0.71). QRISK3 and SCORE2 are equally reliable predictors of carotid plaques in SLE patients. The combination of both calculators offers significantly better discrimination than QRISK3 alone but shows no significant difference when compared with SCORE2 alone. Therefore, SCORE2 alone, without the need for additional tools, can be used to identify patients with SLE who are at high risk of CV events.

28 January 2026 in Lupus
Verified
Journal Article
Closed access
EHElena Heras-Recuero
Elena Heras-Recuero
AGAntía García-Fernández
Antía García-Fernández
PQPatricia Quiroga-Colina
Patricia Quiroga-Colina
CGCristina Gómez-Moreno
Cristina Gómez-Moreno
ATArantxa Torres-Roselló
Arantxa Torres-Roselló
Miguel Angel Gonzalez-GayMiguel Angel Gonzalez-Gay
Miguel Angel Gonzalez-Gay
Objective: To evaluate ethnic disparities among patients with systemic lupus erythematosus (SLE) managed within a universal, publicly funded healthcare system. Methods: Cross-sectional study based on a retrospective review of medical records of patients with SLE who attended the rheumatology outpatient clinics of the Hospital Fundación Jiménez Díaz (Madrid, Spain) between 2023 and 2024. Eligible patients were those who had been followed in the unit at any time between 2010 and 2024 and who met well-established criteria for SLE. Patients of ethnically Spanish origin were classified as Spaniards, while those identified as Latin American (including individuals from South and Central America, and Brazil), Asian, or of African descent were grouped as non-Spaniards. Disease activity was assessed using the SLEDAI and SLEDAS scores, as well as the DORIS remission criteria. Comparative analyses included clinical features, disease activity, and treatment. Group comparisons were performed using the Mann-Whitney U test, Student's t-test, chi-squared test, or Fisher’s exact test, as appropriate. Results: Of the cohort of 324 SLE patients, 42.3% ( n = 137) were non-Spaniards, primarily Latin American (88.3%), followed by Asian (10.2%) and individuals of African descent (1.5%). No significant differences were observed in clinical manifestations or lupus nephritis histology. However, antiphospholipid syndrome was more frequent among Spaniard patients (13.9%) compared to non-Spaniard patients (6.6%) ( p = 0.04). In contrast, anti-Sm antibodies were more commonly detected in non-Spaniards (26.3% vs 16.6%; p = 0.03). Non-Spaniard patients exhibited greater disease activity, with higher mean SLEDAI-2K scores (mean ± standard deviation: 1.80 ± 2.65 vs 1.26 ± 1.84; p = 0.03) and SLE-DAS scores (2.06 ± 3.26 vs 1.34 ± 1.89; p = 0.01), as well as significantly lower DORIS remission rates ( p = 0.03) compared to Spaniard patients. Current prednisone use was 41.3% among non-Spaniard patients versus 24.7% in Spaniards. The use of immunosuppressants was similar between the two groups. Conclusion: In a universal public healthcare system, we did not observe major ethnic disparities in clinical manifestations of SLE. Nonetheless, non-Spaniard patients showed higher disease activity, lower remission rates, and greater glucocorticoid use, suggesting differences in disease expression rather than inequities in care.